Evolus (NASDAQ:EOLS) Downgraded by Wall Street Zen to “Hold”

Evolus (NASDAQ:EOLS) was downgraded by stock analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a report issued on Sunday.

Several other equities analysts have also recently weighed in on EOLS. Stifel Nicolaus lowered their price objective on shares of Evolus from $20.00 to $17.00 and set a “buy” rating on the stock in a research report on Tuesday, January 13th. HC Wainwright reduced their target price on Evolus from $20.00 to $13.00 and set a “buy” rating for the company in a report on Tuesday, February 3rd. Mizuho set a $15.00 target price on Evolus in a research report on Wednesday, February 4th. Needham & Company LLC reiterated a “hold” rating on shares of Evolus in a report on Wednesday, December 24th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Evolus in a research report on Monday, December 22nd. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $16.00.

Evolus Price Performance

Shares of EOLS opened at $5.01 on Friday. The company has a 50-day moving average of $4.89 and a two-hundred day moving average of $6.14. The stock has a market cap of $325.95 million, a price-to-earnings ratio of -6.19 and a beta of 1.02. Evolus has a one year low of $4.09 and a one year high of $13.66.

Evolus (NASDAQ:EOLS) last released its quarterly earnings results on Tuesday, March 3rd. The company reported $0.00 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.09). The firm had revenue of $90.30 million for the quarter, compared to analyst estimates of $89.58 million. Analysts anticipate that Evolus will post -0.61 earnings per share for the current year.

Insider Transactions at Evolus

In other Evolus news, insider David Moatazedi sold 10,539 shares of the stock in a transaction that occurred on Monday, December 22nd. The shares were sold at an average price of $7.15, for a total value of $75,353.85. Following the completion of the sale, the insider owned 354,388 shares in the company, valued at $2,533,874.20. This represents a 2.89% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 5.90% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Evolus

Several institutional investors and hedge funds have recently modified their holdings of EOLS. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Evolus by 5.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 33,289 shares of the company’s stock worth $400,000 after acquiring an additional 1,838 shares during the last quarter. Millennium Management LLC boosted its position in Evolus by 1.7% during the first quarter. Millennium Management LLC now owns 1,392,028 shares of the company’s stock valued at $16,746,000 after purchasing an additional 23,605 shares during the last quarter. Jones Financial Companies Lllp acquired a new stake in Evolus during the first quarter valued at $158,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Evolus by 36.1% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 156,565 shares of the company’s stock valued at $1,883,000 after purchasing an additional 41,513 shares in the last quarter. Finally, Jane Street Group LLC grew its stake in Evolus by 484.8% in the first quarter. Jane Street Group LLC now owns 69,947 shares of the company’s stock valued at $841,000 after purchasing an additional 57,987 shares in the last quarter. 90.69% of the stock is currently owned by hedge funds and other institutional investors.

About Evolus

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.